...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BJU international >High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology.
【24h】

High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology.

机译：前列腺癌的高强度聚焦超声;法国泌尿外科协会的系统文献综述。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We discuss the efficacy and safety of high-intensity focused ultrasound (HIFU) in patients with prostate cancer, to define the best indications for HIFU in daily clinical practice as primary therapy. We searched Medline and Embase for clinical studies evaluating the efficacy and safety of HIFU in prostate cancer (July 2007), and abstracts presented at the 2005-2007 annual meetings of the European Association of Urology and American Urological Association were screened. In all, 37 articles/abstracts were selected. As the data on HIFU as salvage therapy were limited, we focused on HIFU as primary therapy. Studies consisted of case series only. Included patients were approximately 70 years old with T1-T2 N0M0 disease, Gleason Score or=70 years) with T1-T2 N0M0 disease, a Gleason score of <7, a PSA level of <15 ng/mL and a prostate volume of <40 mL. In these patients HIFU achieves short-term cancer control, as shown by a high percentage of negative biopsies and significantly reduced PSA levels. The median-term survival data also seem promising, but long-term follow-up studies are needed to further evaluate cancer-specific and overall survival rates before the indications for primary therapy can be expanded.
机译：我们讨论高强度聚焦超声（HIFU）在前列腺癌患者中的疗效和安全性，以定义HIFU在日常临床实践中作为主要疗法的最佳适应症。我们检索了Medline和Embase进行临床研究，以评估HIFU在前列腺癌中的疗效和安全性（2007年7月），并筛选了在欧洲泌尿外科协会和美国泌尿外科协会2005-2007年度会议上发表的摘要。总共选择了37篇文章/摘要。由于有关HIFU作为挽救疗法的数据有限，因此我们将HIFU作为主要疗法。研究仅包括病例系列。纳入的患者约为70岁，患有T1-T2 N0M0疾病，格里森评分<或= 7，前列腺特异性抗原（PSA）水平<或= 28 ng / mL，前列腺体积<或= 40 mL。 Ablatherm设备（EDAP TMS S.A.，法国Vaulx-en-Velin，法国）的活检阴性率为64-93％，并且55-84％的患者的PSA最低点为<0.5 ng / mL。 5年精算无病生存率为60-70％。最常见的并发症是压力性尿失禁，尿路感染，尿道/膀胱颈狭窄或狭窄以及勃起功能障碍。对于Ablatherm器械，由于该器械的技术改进以及在HIFU前使用经尿道前列腺电切术，并发症的发生率多年来已大大降低。总之，HIFU是T1-T2 N0M0疾病，格里森评分<7，PSA水平<15 ng / mL，前列腺体积为20的老年患者（>或= 70岁）适用于前列腺癌的主要疗法。 <40 mL。在这些患者中，HIFU可实现短期癌症控制，如高百分比的阴性活检和显着降低的PSA水平所显示。中位生存期数据似乎也很有希望，但是需要在长期的随访研究中进一步评估癌症特异性生存率和总体生存率，然后才能扩大主要治疗的适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号